| |
| |
|
| Insider
Information: |
Hershberg Robert |
| Relationship: |
|
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,311,047 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$16,514,461 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,311,047 |
|
|
| Total
Value |
$16,514,461 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -94.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Dendreon Corp |
DNDN |
Sr. VP & Chief Medical... |
2006-01-19 |
15,724 |
2006-01-19 |
0 |
Premium* |
|
|
Adaptive Biotechnologies Corp |
ADPT |
Director |
2024-03-04 |
107,296 |
2020-04-23 |
0 |
Premium* |
|
|
Nanostring Technologies Inc |
NSTG |
Director |
2022-04-18 |
10,716 |
2020-05-15 |
0 |
Premium* |
|
|
Recursion Pharmaceuticals, Inc. |
RXRX |
Director |
2023-06-16 |
38,619 |
2021-04-16 |
0 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2022-06-09 |
10,659 |
2021-06-02 |
0 |
Premium* |
|
|
Hillevax, Inc. |
HLVX |
|
2024-02-08 |
1,128,033 |
2023-02-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADPT |
Adaptive Biotechnologies ... |
Director |
– • – |
2024-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
31,328 |
107,296 |
0 |
- |
|
| HLVX |
Hillevax, Inc. |
See Remarks |
• • – |
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
174,202 |
1,128,033 |
0 |
- |
|
| HLVX |
Hillevax, Inc. |
See Remarks |
• • – |
2024-02-08 |
4 |
S |
$14.93 |
$173,161 |
D/D |
(11,597) |
953,831 |
0 |
% |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2023-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,612 |
38,619 |
0 |
- |
|
| ADPT |
Adaptive Biotechnologies ... |
Director |
– • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,775 |
75,968 |
0 |
- |
|
| ADPT |
Adaptive Biotechnologies ... |
Director |
– • – |
2023-02-02 |
4 |
OE |
$0.45 |
$23,850 |
D/D |
53,000 |
61,193 |
0 |
- |
|
| HLVX |
Hillevax, Inc. |
President and CEO |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
187,966 |
965,428 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
26,007 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
10,659 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.75 |
$15,288 |
D/D |
(672) |
2,009 |
0 |
% |
|
| NSTG |
Nanostring Technologies I... |
Director |
– • – |
2022-04-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,306 |
10,716 |
0 |
- |
|
| ADPT |
Adaptive Biotechnologies ... |
Director |
– • – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,689 |
8,193 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
693 |
7,862 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
572 |
7,169 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
347 |
6,597 |
0 |
- |
|
| NSTG |
Nanostring Technologies I... |
Director |
– • – |
2021-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,520 |
7,410 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,681 |
2,681 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
0 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
6,250 |
0 |
- |
|
| RXRX |
Recursion Pharmaceuticals... |
Director |
– • – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
6,250 |
0 |
- |
|
| NSTG |
Nanostring Technologies I... |
Director |
– • – |
2021-04-15 |
4 |
AS |
$71.75 |
$10,642 |
D/D |
(144) |
1,890 |
0 |
% |
|
| NSTG |
Nanostring Technologies I... |
Director |
– • – |
2021-04-15 |
4 |
OE |
$14.71 |
$2,118 |
D/D |
144 |
2,034 |
0 |
- |
|
| NSTG |
Nanostring Technologies I... |
Director |
– • – |
2021-03-15 |
4 |
AS |
$63.58 |
$100,407 |
D/D |
(1,500) |
1,890 |
0 |
% |
|
| NSTG |
Nanostring Technologies I... |
Director |
– • – |
2021-03-15 |
4 |
OE |
$11.20 |
$16,800 |
D/D |
1,500 |
3,390 |
0 |
- |
|
| ADPT |
Adaptive Biotechnologies ... |
Director |
– • – |
2021-03-08 |
4 |
OE |
$0.45 |
$900 |
D/D |
2,000 |
2,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
